Mallinckrodt PLC (MNK)

47.42
0.71 1.52
NYSE : Health Care
Prev Close 46.71
Open 46.99
Day Low/High 46.74 / 47.86
52 Wk Low/High 38.80 / 85.83
Volume 1.98M
Avg Volume 2.18M
Exchange NYSE
Shares Outstanding 99.35M
Market Cap 4.64B
EPS 5.80
P/E Ratio 25.52
Div & Yield N.A. (N.A)

Latest News

Mallinckrodt Finalizes Previously Announced Agreement With DEA And USAOs

Mallinckrodt Finalizes Previously Announced Agreement With DEA And USAOs

-- Mallinckrodt Reaffirms Industry-Leading Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products --

Mallinckrodt Announces Specialty Brands Investor Briefing

Mallinckrodt Announces Specialty Brands Investor Briefing

-- R&D-Focused Event to Highlight Commercial Portfolio and Growing Pipeline --

Health Economic Data On Burden Of Hepatorenal Syndrome Published In Current Medical Research And Opinion

-- Long Hospital Stays, Frequent Medical Visits and Hospital Readmissions Drive Costs, Payer Burden --

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Mallinckrodt Enrolls First Patient In Phase 2B Trial Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS)

--Mallinckrodt's PENNANT Trial to Assess Efficacy and Safety of H.P. Acthar Gel in ALS Patients--

Mallinckrodt Enrolls First Patient In Phase 3 Trial Of StrataGraft® Regenerative Skin Tissue

-- Trial to Assess Efficacy and Safety in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements --

Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop

Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop

Wall Street wasn't able to extend a record-breaking streak into a third session on Monday after a terror attack in London.

Closing Bell: Stocks Snap Two-Day Winning Streak; Apple to Add Amazon prime to Apple TV

Closing Bell: Stocks Snap Two-Day Winning Streak; Apple to Add Amazon prime to Apple TV

Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.

Stocks Mostly Lower in Cautious Trading, Apple Slips on Downgrade

Stocks Mostly Lower in Cautious Trading, Apple Slips on Downgrade

Stocks are mostly lower on Monday after a terror attack in London over the weekend and following a rare analyst downgrade on Apple shares.

Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication

Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication

Citron attacked Mallinckrodt's partnership with Express Scripts ESRX, liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant.

Mallinckrodt Inquires Into Sale of Generic Drug Unit

Mallinckrodt Inquires Into Sale of Generic Drug Unit

Shares of drug maker Mallinckrodt were falling Wednesday afternoon

Mallinckrodt Explores Sale of Generic Drug Unit

Mallinckrodt Explores Sale of Generic Drug Unit

The unit accounted for about 30% of the company's revenue in the first quarter.

Behind the War Between Health Insurers and Pharmacy Benefit Managers

Behind the War Between Health Insurers and Pharmacy Benefit Managers

More competition could help overcome the suspicion over drug prices that plagues the would-be business partners' dealings.

Mallinckrodt Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse

-- Preliminary Demographic Data on Currently Enrolled Patients to be Presented at the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers [Poster RT01] --

First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse

-- Mallinckrodt's OPTIONS Trial to Assess Efficacy and Safety of H.P. Acthar Gel in Patients with Relapsing-Remitting Multiple Sclerosis --

Two More Stock Picks From Hedge Fund Leaders at SALT

Two More Stock Picks From Hedge Fund Leaders at SALT

Kynikos Associates' James Chanos, famous for his shorting campaign at Enron, on Thursday presented a short campaign.

First Patient Enrolled In Mallinckrodt Phase 2 Trial Of StrataGraft® Regenerative Skin Tissue

-- Mallinckrodt's Trial to Assess Safety, Tolerability, and Efficacy as an Alternative to Autografting Full-thickness Complex Skin Defects --

100 Days, 10 Tweets: How Donald Trump Ruled the Market 140 Characters at a Time

100 Days, 10 Tweets: How Donald Trump Ruled the Market 140 Characters at a Time

A look at Trump's first 100 days in office in 140 characters or less.

Mallinckrodt Data From New Company-Sponsored Studies Presented At American Academy Of Neurology 69th Annual Meeting

-- Results of treating physician survey suggest treatment with H.P. Acthar® Gel (repository corticotropin injection) among patients with infantile spasms may reduce medical resource utilization, including emergency room visits, hospitalizations and days hospitalized [Poster 219] --

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.